Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement the Phase 2 trial of Lucid-MS, its lead drug candidate for multiple sclerosis. The agreement marks a critical step in moving Lucid-MS from planning into execution, enlisting a global contract research organization with deep expertise in central nervous system and MS studies.
The significance of this partnership lies in the novel mechanism of action of Lucid-MS. Most existing MS drugs work by quieting the immune system to reduce inflammation and prevent relapses. Lucid-MS, however, is designed around a neuroprotective approach that targets demyelination—the loss of the protective myelin sheath around nerve fibers—rather than solely modulating the immune system. If successful, this could represent a paradigm shift in MS treatment, offering a therapy that directly protects nerves and potentially slows or reverses disability progression, a major unmet need in MS care.
Thermo Fisher's clinical research business brings extensive experience in conducting complex CNS trials, which is crucial for a Phase 2 study that will need to carefully assess both safety and efficacy signals. The agreement covers study start-up activities, including site selection, regulatory preparations, and operational planning, setting the stage for patient enrollment. For Quantum BioPharma, this collaboration provides the infrastructure and expertise needed to rigorously test its innovative approach, potentially accelerating development timelines.
Investors and industry observers will be watching closely, as positive Phase 2 results could validate a new therapeutic strategy for MS, a market currently dominated by immune-modulating drugs. The trial also represents a significant milestone for Quantum BioPharma, transitioning from preclinical planning to clinical execution. The company's newsroom, available at https://ibn.fm/QNTM, will provide ongoing updates.
The announcement was disseminated through InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. The full press release can be read at Read More>>. For terms of use and disclaimers, visit https://www.InvestorWire.com/Disclaimer.
